<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04740463</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL21_0033</org_study_id>
    <nct_id>NCT04740463</nct_id>
  </id_info>
  <brief_title>Assessement of Capacity to Consent</brief_title>
  <official_title>Assessement of Capacity to Consent in Depressed Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Any patient can request euthanasia in many of our neighbouring European countries as long as&#xD;
      informed consent is given. Psychiatric evaluation is not always mandatory.&#xD;
&#xD;
      Faced with the increasing emergence of euthanasia requests in different countries from&#xD;
      patients under psychiatric care in France for severe depressive episodes, question arises of&#xD;
      a possible alteration in the capacity to give consent in the context of a severe depressive&#xD;
      episode.&#xD;
&#xD;
      This is a Social and Human Sciences study which does not aim to modify the usual management&#xD;
      of patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Capacity to consent (MacCAT-T)</measure>
    <time_frame>1 day</time_frame>
    <description>aassessment of the capacity to consent based on the MacArthur Competence Assessment Tool-Treatment (MacCAT-T). The questionnaire assesses four competences in consent : understanding (score ranges from 0 to 6), appreciation (score ranges from 0 to 4), reasoning (score ranges from 0 to 8) and expressing a choice (score ranges from 0 to 2).&#xD;
A low score on each of these dimensions calls into question the patient's ability to consent.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insight (BCIS)</measure>
    <time_frame>1 day</time_frame>
    <description>insight assessement based on the Beck Cognitive Insight Scale (BCIS). The questionnaire contains two sub-scales : self- reflection (9 items) and self-certainty (6 items). Each items ranges from 0 (do not agree at all) to 3 (agree completely)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Depression (BDI)</measure>
    <time_frame>1 day</time_frame>
    <description>depression assesement based on the Beck Depression Inventory (BDI) score. Total score ranges from 0 to 63. Higher scores indicate more severe depression symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Depression (MADRS)</measure>
    <time_frame>1 day</time_frame>
    <description>depression assessement based on the Montgomery Asberg Depression Rating Scale (MADRS) score. Total score ranges from 0 to 60. Higher scores indicate more severe depression symptoms.</description>
  </other_outcome>
  <other_outcome>
    <measure>Suicidality (MADRS)</measure>
    <time_frame>1 day</time_frame>
    <description>suicidality assessement based on the 10th MADRS item. The item ranges from 0 (enjoys life or takes it as it come) to 6 (explicit plans for suicide when there is an opportunity. Active preparations for suicide).</description>
  </other_outcome>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Major Depressive Episode</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Depressed patients (consultation or hospitalization)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Age between 18 and 75&#xD;
&#xD;
          -  Ability to understand and participate in the interview&#xD;
&#xD;
          -  French-speaking&#xD;
&#xD;
          -  Presence of a current characterized depressive episode according to DSM-5 diagnostic&#xD;
             criteria&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        - Refusal to participate&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emilie Olie, MD PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Olie, MD PhD</last_name>
    <phone>+33 4 67 33 85 81</phone>
    <email>e-olie@chu-montpellier.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Thomas CATANZARO, MD (intern)</last_name>
    <phone>4 67 33 82 89</phone>
    <phone_ext>33</phone_ext>
    <email>t-catanzaro@chu-montpellier.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilie OLIE, MD PhD</last_name>
      <phone>4 67 33 82 89</phone>
      <phone_ext>33</phone_ext>
      <email>e-olie@chu-montpellier.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 2, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2021</study_first_posted>
  <last_update_submitted>May 18, 2021</last_update_submitted>
  <last_update_submitted_qc>May 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Capacity to consent</keyword>
  <keyword>Euthanasia</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>NC</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

